ACR publishes coronavirus use case to help AI researchers

The American College of Radiology Data Science Institute (ACR DSI) has shared an AI use case for the new coronavirus, publishing it just as the World Health Organization declared COVID-19 a pandemic.

The hope is that this use case can contribute to the development of an AI model that can detect signs of COVID-19 on imaging results.

“Expert radiologists rapidly developed the use case to offer the developer community medical context—including necessary inputs, outputs and possible corollary features— or developing an AI solution to detect COVID-19,” according to a statement from the ACR DSI. “Patients with the virus present with several unique clinical characteristics. Early published reports suggest an increasing role for chest computed tomography scans in the detection and diagnosis of COVID-19.”

“Such an AI solution may prove to be a very useful application towards COVID-19 diagnosis and containment,” Eric Stern, MD, chair of the ACR DSI Thoracic Panel, said in the same statement.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.